Please login to the form below

Not currently logged in
Email:
Password:

Boehringer to buy Amgen's California facility

Boehringer Ingelheim is to purchase the rights to all assets at Amgen's development and manufacturing facility in Fremont, California

Boehringer Ingelheim is to purchase the rights to all assets at Amgen's development and manufacturing facility in Fremont, California.

The deal will go through by the end of March, 2011, with Germany-based pharma company Boehringer taking control of the biotech's plant and workforce of 360 employees. The plant was obtained by Amgen following its acquisition of biopharma Abgenix in 2006.

Financial details of Boehringer's takeover were not disclosed.

"With great enthusiasm, we look forward to welcoming the Amgen Fremont employees into the Boehringer Ingelheim family of companies," said Professor Dr Wolfram Carius, Boehringer Ingelheim board of managing directors. "The technological expertise at Fremont and the state-of-the-art facility will enable us to further strengthen our global contract manufacturing business including new biological entity process development and manufacturing efforts."

Boehringer has had a relationship with Amgen for more than 10 years, acting as a contract manufacturer for products developed by Amgen.

Dr Fabrizio Bonanni, executive vice president of operations, Amgen, said: "We look forward to continuing to work closely with [Boehringer] to support Amgen's delivery of safe and effective medicines to patients around the world."

19th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics